<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89921</article-id><article-id pub-id-type="pmcid-ver">PMC89921.1</article-id><article-id pub-id-type="pmcaid">89921</article-id><article-id pub-id-type="pmcaiid">89921</article-id><article-id pub-id-type="pmid">10817717</article-id><article-id pub-id-type="doi">10.1128/aac.44.6.1609-1615.2000</article-id><article-id pub-id-type="publisher-id">0783</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Antiviral Agents</subject></subj-group></article-categories><title-group><article-title>Absolute Bioavailability and Disposition of (&#8722;) and (+) 2&#8242;-Deoxy- 3&#8242;-Oxa-4&#8242;-Thiocytidine (dOTC) following Single Intravenous  and Oral Doses of Racemic dOTC in Humans</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="PF">Patrick F.</given-names></name><xref ref-type="aff" rid="N0x8c1e010.0x968f988">1</xref><xref ref-type="aff" rid="N0x8c1e010.0x968f988">2</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Forrest</surname><given-names initials="A">Alan</given-names></name><xref ref-type="aff" rid="N0x8c1e010.0x968f988">1</xref><xref ref-type="aff" rid="N0x8c1e010.0x968f988">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ballow</surname><given-names initials="CH">Charles H.</given-names></name><xref ref-type="aff" rid="N0x8c1e010.0x968f988">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martin</surname><given-names initials="DE">David E.</given-names></name><xref ref-type="aff" rid="N0x8c1e010.0x968f988">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Proulx</surname><given-names initials="L">Louise</given-names></name><xref ref-type="aff" rid="N0x8c1e010.0x968f988">4</xref></contrib></contrib-group><aff id="N0x8c1e010.0x968f988"> The State University of New York at Buffalo School of Pharmacy,<sup>1</sup> and  Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital,<sup>2</sup> Buffalo, New York;  PharmaResearch Corporation, Morrisville, North Carolina<sup>3</sup>; and  BioChem Pharma Inc., Laval, Canada<sup>4</sup></aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: State University of NY at Buffalo, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Phone: (716) 845-3281. Fax: (716) 845-2336. E-mail: <email>Pfsmith@acsu.buffalo.edu</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>6</month><year>2000</year></pub-date><volume>44</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">2485</issue-id><fpage>1609</fpage><lpage>1615</lpage><history><date date-type="received"><day>15</day><month>9</month><year>1999</year></date><date date-type="rev-request"><day>31</day><month>1</month><year>2000</year></date><date date-type="accepted"><day>16</day><month>3</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-10-31 10:56:17.363"><day>31</day><month>10</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac001609.pdf"/><abstract><p>The purpose of this study was to characterize the pharmacokinetics and determine the absolute bioavailability of 2&#8242;-deoxy-3&#8242;-oxa-4&#8242;-thiocytidine (dOTC) (BCH-10652), a novel nucleoside analogue reverse transcriptase inhibitor, in humans. dOTC belongs to the 4&#8242;-thio heterosubstituted class of compounds and is a 1:1 mixture of its two enantiomers, (&#8722;) and (+) dOTC. Twelve healthy adult male volunteers each received oral (800-mg) and intravenous (100-mg) doses of dOTC in two study periods separated by at least 7 days. Sixteen plasma samples were obtained over 72 h and assayed for (&#8722;) and (+) dOTC, and the resultant data fit by candidate pharmacokinetic models. Data were weighted by the fitted inverse of the observation variance; model discrimination was by AIC. The pharmacokinetic model was a linear, three compartment model, with absorption occurring during one to three first-order input phases, each following a fitted lag time. The model goodness-of-fit was excellent; <italic>r</italic><sup>2</sup> ranged from 0.995 to 1.0. The mean absolute bioavailabilities of (+) and (&#8722;) dOTC were 77.2% (coefficient of variation [given as a percentage] [CV%], 14) and 80.7% (CV%, 15), respectively. The median steady-state volume of distribution for (+) dOTC, 74.7 (CV%, 19.2) liters/65 kg, was greater than that for (&#8722;) dOTC, 51.7 (CV%, 16.7) liters/65 kg (<italic>P</italic> &lt; 0.05). The median total clearance of (+) dOTC was less than that of (&#8722;) dOTC, 11.7 (CV%, 17.3) versus 15.4 (CV%, 18.6) liters/h/65 kg, respectively (<italic>P</italic> &lt; 0.05). The intersubject variability of these parameters was very low. The median terminal half-life of (+) dOTC was 18.0 (CV%, 31.5) h, significantly longer than the 6.8 (CV%, 69.9) h observed for (&#8722;) dOTC (<italic>P</italic> &lt; 0.01). No serious adverse events were reported during the study. These results suggest that dOTC is well absorbed, widely distributed, and well tolerated. The terminal half-lives indicate that dosing intervals of 12 to 24 h would be reasonable.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>